NeXtGen Biologics develops NeoMatriX®, a sterile collagen wound matrix derived from the axolotl extracellular matrix, to create a regenerative environment for partial‑ and full‑thickness skin wounds. The device delivers bioactive cues that promote rapid, scar‑free tissue closure, with clinical data showing up to 64% closure of diabetic ulcers in one week. It is intended for wound‑care clinicians, dermatologic surgeons, and hospital wound‑management programs seeking advanced regenerative solutions.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with partial or full-thickness wounds, such as diabetic ulcers or post‑surgical sites, often experience slow healing and scar formation, leading to prolonged treatment, higher infection risk, and reduced quality of life.
Solution
NeXtGen Biologics offers NeoMatriX®, a medical device composed of collagen matrices derived from the extracellular matrix of the axolotl, an organism renowned for scar‑free regeneration. The axolotl‑derived matrix creates a regenerative wound environment that supports rapid tissue closure without scar tissue. Clinical data demonstrate accelerated healing, including 64% closure of diabetic ulcers within one week and successful closure of Mohs surgery sites. By leveraging natural regenerative biology, NeoMatriX® provides clinicians with a biologically active scaffold that promotes native tissue regeneration rather than mere tissue replacement.
Target Audience
Primary customers are wound‑care clinicians, dermatologic surgeons, and hospital wound‑management programs seeking advanced regenerative solutions for chronic and acute skin defects.
Features
- Collagen wound matrix sourced from axolotl extracellular matrix, preserving bioactive cues for regeneration
- Designed for both partial‑thickness and full‑thickness wounds, including chronic ulcers and surgical defects
- Promotes scar‑free healing by mimicking the axolotl’s natural regenerative pathways
- Ready‑to‑use sterile medical device compatible with standard wound‑care protocols
- Demonstrated clinical efficacy with rapid closure rates in diabetic ulcers and post‑Mohs surgery sites